Account
Inquiry
Liraglutide (CAS 204656-20-2) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of endogenous GLP-1, stimulating insulin secretion while inhibiting glucagon release. This dual action makes it particularly effective for managing type 2 diabetes and promoting weight loss.
The mechanism of action involves binding to GLP-1 receptors, which are located in pancreatic beta cells. This binding stimulates glucose-dependent insulin secretion while simultaneously reducing glucagon secretion. Additionally, Liraglutide slows gastric emptying and reduces appetite, contributing to its weight loss effects.
Clinical studies have demonstrated that Liraglutide can lead to significant reductions in HbA1c levels (typically 1.0-1.5%) and body weight (average 4-8% reduction). The weight loss effects are particularly notable when used at higher doses specifically approved for obesity treatment.
Compared to other GLP-1 agonists, Liraglutide offers several advantages. Its prolonged half-life (approximately 13 hours) allows for once-daily dosing, improving patient compliance. The molecule features a fatty acid side chain that promotes binding to albumin, extending its duration of action while maintaining the biological activity of native GLP-1.
Our Liraglutide is produced under strict GMP conditions with rigorous quality control at every production stage. The product undergoes comprehensive analytical testing including HPLC purity analysis, mass spectrometry confirmation, and sterility testing to ensure pharmaceutical-grade quality.
Storage conditions are critical for maintaining peptide stability. Liraglutide should be stored at controlled room temperature (15-25°C) or refrigerated (2-8°C) for long-term storage. The lyophilized powder form offers excellent stability and shelf life when properly stored.
